SCHEMBL17079240

SCHEMBL17079240

CC(C)C(=O)NNC(=O)CCNC(=O)c1cc(-c2ccccc2)on1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.59
HDAC1 Q13547 1/20 0.59
HDAC2 Q92769 1/20 0.59
HDAC10 Q969S8 1/20 0.59
HDAC8 Q9BY41 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
HIF1A Q16665 4/20 0.59
FAAH O00519 4/20 0.57
TP53 P04637 1/20 0.53
KMT2A Q03164 3/20 0.52
LMNA P02545 3/20 0.52
POLB P06746 1/20 0.52
RAB9A P51151 4/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
NPC1 O15118 3/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 2/20 0.50
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17079246 0.85 HDAC3 (0.51) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL17079248 0.85 HDAC3 (0.51) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL17087757 0.85 HDAC3 (0.51) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL26079027 0.83 HIF1A (0.67) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL17079180 0.82 HDAC6 (0.58) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL17087759 0.81 HIF1A (0.67) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL17079182 0.81 HIF1A (0.73) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL17079252 0.81 HDAC3 (0.57) HDAC3HDAC1HDAC2HDAC10HDAC8
Hydrochloric Acid SCHEMBL17079188 0.80 HDAC3 (0.65) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL23822956 0.80 HIF1A (0.61) HDAC3HDAC1HDAC2HDAC10HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790219-B2 Compounds, compositions, and methods for increasing CFTR activity PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
US-9790219-B2 Compounds, compositions, and methods for increasing CFTR activity PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
US-9790219-B2 Compounds, compositions, and methods for increasing CFTR activity PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
EP-3116501-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY Proteostasis Therapeutics, Inc. (US) 2017-01-18 EP disclosed
US-20170001993-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. 2017-01-05 US disclosed
US-20170001993-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. 2017-01-05 US disclosed
US-20170001993-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. 2017-01-05 US disclosed
WO-2015138909-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. (US) 2015-09-17 WO disclosed
WO-2015138909-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. (US) 2015-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170001993-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY CFTR, ABCB4, KEAP1 HDAC3 1519/4885HDAC1 1921/4885HDAC2 2961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.